Pluristem Therapeutics Inc. Company Profile

05:55 EDT 18th March 2018 | BioPortfolio

Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. In April 2010, Pluristem reported interim top-line results from Phase I clinical trials of PLX-PAD that demonstrated the cell therapy is potentially safe, well tolerated and effective in patients with critical limb ischemia (CLI).

News Articles [783 Associated News Articles listed on BioPortfolio]

Pluristem Therapeutics (PSTI) - Progress continues

Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Pluristem Therapeutics has had a productive FY18 to date. The company is advancing PLX-PAD in its Phase III study of ...

Why Pluristem Therapeutics believe that in cell therapy “the process is the product”

Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics

William Prather, of Pluristem Therapeutics, discusses the change in the way pharmaceutical companies look at cell based therapies

In this episode of PharmaTelevision News Review, filmed at BIO 2011, Fintan Walton talks to William R. Prather, Senior Vice President Corporate Development of Pluristem Therapeutics inc.

Pluristem Therapeutics (PSTI) - New avenues of study

Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Pluristem continues to advance its PLX technology platform. In a recent paper it investigated the application of thes...

Pluristem Therapeutics (PSTI) - Grants and collaborations to support development

Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Pluristem now has three ongoing clinical programs: critical limb ischemia (CLI, Phase III), intermittent claudication...

Converting medical waste to therapeutics for all: Zami Aberman, CEO and Chairman, Pluristem

In cell therapy the process is the product. Pluristem’s 3D expansion technology allows for the production of different PLX cell products. . Pluristem manufactures therapeutic cell products using hu...

FDA gives orphan status to Pluristem's acute radiation syndrome drug

Pluristem Therapeutics' PLX-R18, which is being developed as a treatment for patients with acute radiation syndrome, was gran -More- 

FDA clears expanded access programme for Pluristem’s PLX-PAD cell treatment

The US Food and Drug Administration (FDA) has cleared the expanded access programme (EAP), submitted by Pluristem Therapeutics, for the use of PLX-PAD cell treatment in patients with critical limb isc...

PubMed Articles [405 Associated PubMed Articles listed on BioPortfolio]

Optimization of culture conditions for the derivation and propagation of baboon (Papio anubis) induced pluripotent stem cells.

Induced pluripotent stem cells (iPSCs) offer the possibility of cell replacement therapies using patient-matched cells to treat otherwise intractable diseases and debilitations. To successfully realiz...

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 1 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [134 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1199 Associated Companies listed on BioPortfolio]

Pluristem Therapeutics Inc.

Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Pluristem Therapeutics Inc." on BioPortfolio

We have published hundreds of Pluristem Therapeutics Inc. news stories on BioPortfolio along with dozens of Pluristem Therapeutics Inc. Clinical Trials and PubMed Articles about Pluristem Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pluristem Therapeutics Inc. Companies in our database. You can also find out about relevant Pluristem Therapeutics Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Corporate Database Quicklinks

Searches Linking to this Company Record